Melphalan therapy for plasma cell myeloma.
Melphalan therapy for plasma cell myeloma.
复制标题
马法兰治疗浆细胞骨髓瘤。
作者：
R. Alexanian;D. Bergsagel;P. Migliore;W. Vaughn;C. Howe
在接受美法仑治疗的 82 名浆细胞骨髓瘤患者中，40 名（49%）的临床状态和疾病的直接表现得到改善。骨髓瘤蛋白水平为定期评估疾病活动性提供了重要参数。有效化疗后，尿液中的骨髓瘤球蛋白比血清中下降得更快、程度更大。大多数有反应的患者贫血和低蛋白血症得到改善，从而支持这些参数在确认临床反应中的有用性。所有患者的中位生存时间为出现症状后 42 个月、诊断后 34 个月、马法兰治疗后 23 个月。有反应的患者的寿命延长了两年以上，这一时期是根据客观反应的持续时间来计算的。浆细胞骨髓瘤治疗的未来进展将更多地取决于化疗的进展，而不是支持治疗的改进。
Of 82 patients with plasma cell myeloma treated with melphalan, 40 (49 per cent) were improved in clinical status and in a direct manifestation of disease. Myeloma protein level provided an important parameter for periodic assessment of disease activity. After effective chemotherapy, myeloma globulins decreased more rapidly and to a greater degree in urine than in serum. Anemia and hypoalbuminemia were improved in most responding patients, thus supporting the usefulness of these parameters in confirming clinical response. Median survival time for all patients was 42 months from symptoms, 34 months from diagnosis, and 23 months from melphalan. The life-span of responding patients was prolonged more than 2 years, a period accounted for by the duration of objective response. Future progress in treatment for plasma cell myeloma will depend more on advances in chemotherapy than upon improvements in supportive care.